EGFR and non-small cell lung carcinoma: The results (Table 2) showed that the three core anti-NSCLC compounds had good affinity with all six key targets (binding energy < −5 kcal/mol); among them, epicatechin exhibited strong binding activity with TP53 and EGFR (binding energy < −7 kcal/mol).